APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rheumatic Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Rheumatic Disease Drugs Market Analysis and Forecast 2026-2032

23 December 2025207 pages

Choose your research edition.

Industry ResearchRheumatic Disease Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Rheumatic Disease Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Rheumatic Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rheumatic Disease Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Rheumatic Disease Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Rheumatic Disease Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Rheumatic Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Rheumatic Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Rheumatic Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Rheumatic Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Rheumatic Disease Drugs include Simcere, WuXi AppTec, Sanofi, Johnson & Johnson, Roche, Eli Lilly and Company, ALPHAMAB ONCOLOGY, Hengrui and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Rheumatic Disease Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Rheumatic Disease Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Rheumatic Disease Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rheumatic Disease Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Rheumatic Disease Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Rheumatic Disease Drugs revenue, projected growth trends, production technology, application and end-user industry.

Rheumatic Disease Drugs Segment by Company

Simcere

WuXi AppTec

Sanofi

Johnson & Johnson

Roche

Eli Lilly and Company

ALPHAMAB ONCOLOGY

Hengrui

Pfizer

Henlius

Bristol-Myers Squibb

Amgen

AbbVie

UCB

Mitsubishi Tanabe Pharma Corporation

IQVIA

Boehringer-Ingelheim

Aprazer

Rheumatic Disease Drugs Segment by Type

DMARDs

JAK Inhibitors

Biologics

Others

Rheumatic Disease Drugs Segment by Application

Hospital

Clinic

Others

Rheumatic Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rheumatic Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rheumatic Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rheumatic Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Rheumatic Disease Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Rheumatic Disease Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rheumatic Disease Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Rheumatic Disease Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. DMARDs Major Player Table 3. JAK Inhibitors Major Player Table 4. Biologics Major Player Table 5. Others Major Player Table 6. Global Rheumatic Disease Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Clinic Major Player Table 9. Others Major Player Table 10. Rheumatic Disease Drugs Industry Trends Table 11. Rheumatic Disease Drugs Industry Drivers Table 12. Rheumatic Disease Drugs Industry Opportunities and Challenges Table 13. Rheumatic Disease Drugs Industry Restraints Table 14. Global Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Rheumatic Disease Drugs Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Rheumatic Disease Drugs Market Share by Region (2021-2026) Table 17. Global Rheumatic Disease Drugs Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Rheumatic Disease Drugs Market Share by Region (2027-2032) Table 19. Global Rheumatic Disease Drugs Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Rheumatic Disease Drugs Revenue Market Share by Players (2021-2026) Table 21. Global Rheumatic Disease Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Rheumatic Disease Drugs Key Players Headquarters & Area Served Table 23. Global Rheumatic Disease Drugs Players, Product Type & Application Table 24. Global Rheumatic Disease Drugs Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Rheumatic Disease Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Rheumatic Disease Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Rheumatic Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Rheumatic Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Rheumatic Disease Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Rheumatic Disease Drugs Revenue Market Share by Type (2027-2032) Table 32. Global Rheumatic Disease Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Rheumatic Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Rheumatic Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Rheumatic Disease Drugs Revenue Market Share by Application (2021-2026) Table 36. Global Rheumatic Disease Drugs Revenue Market Share by Application (2027-2032) Table 37. Simcere Company Information Table 38. Simcere Business Overview Table 39. Simcere Rheumatic Disease Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Simcere Rheumatic Disease Drugs Product Portfolio Table 41. Simcere Recent Development Table 42. WuXi AppTec Company Information Table 43. WuXi AppTec Business Overview Table 44. WuXi AppTec Rheumatic Disease Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. WuXi AppTec Rheumatic Disease Drugs Product Portfolio Table 46. WuXi AppTec Recent Development Table 47. Sanofi Company Information Table 48. Sanofi Business Overview Table 49. Sanofi Rheumatic Disease Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Sanofi Rheumatic Disease Drugs Product Portfolio Table 51. Sanofi Recent Development Table 52. Johnson & Johnson Company Information Table 53. Johnson & Johnson Business Overview Table 54. Johnson & Johnson Rheumatic Disease Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Johnson & Johnson Rheumatic Disease Drugs Product Portfolio Table 56. Johnson & Johnson Recent Development Table 57. Roche Company Information Table 58. Roche Business Overview Table 59. Roche Rheumatic Disease Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Roche Rheumatic Disease Drugs Product Portfolio Table 61. Roche Recent Development Table 62. Eli Lilly and Company Company Information Table 63. Eli Lilly and Company Business Overview Table 64. Eli Lilly and Company Rheumatic Disease Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Eli Lilly and Company Rheumatic Disease Drugs Product Portfolio Table 66. Eli Lilly and Company Recent Development Table 67. ALPHAMAB ONCOLOGY Company Information Table 68. ALPHAMAB ONCOLOGY Business Overview Table 69. ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Product Portfolio Table 71. ALPHAMAB ONCOLOGY Recent Development Table 72. Hengrui Company Information Table 73. Hengrui Business Overview Table 74. Hengrui Rheumatic Disease Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Hengrui Rheumatic Disease Drugs Product Portfolio Table 76. Hengrui Recent Development Table 77. Pfizer Company Information Table 78. Pfizer Business Overview Table 79. Pfizer Rheumatic Disease Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Pfizer Rheumatic Disease Drugs Product Portfolio Table 81. Pfizer Recent Development Table 82. Henlius Company Information Table 83. Henlius Business Overview Table 84. Henlius Rheumatic Disease Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Henlius Rheumatic Disease Drugs Product Portfolio Table 86. Henlius Recent Development Table 87. Bristol-Myers Squibb Company Information Table 88. Bristol-Myers Squibb Business Overview Table 89. Bristol-Myers Squibb Rheumatic Disease Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Bristol-Myers Squibb Rheumatic Disease Drugs Product Portfolio Table 91. Bristol-Myers Squibb Recent Development Table 92. Amgen Company Information Table 93. Amgen Business Overview Table 94. Amgen Rheumatic Disease Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Amgen Rheumatic Disease Drugs Product Portfolio Table 96. Amgen Recent Development Table 97. AbbVie Company Information Table 98. AbbVie Business Overview Table 99. AbbVie Rheumatic Disease Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. AbbVie Rheumatic Disease Drugs Product Portfolio Table 101. AbbVie Recent Development Table 102. UCB Company Information Table 103. UCB Business Overview Table 104. UCB Rheumatic Disease Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. UCB Rheumatic Disease Drugs Product Portfolio Table 106. UCB Recent Development Table 107. Mitsubishi Tanabe Pharma Corporation Company Information Table 108. Mitsubishi Tanabe Pharma Corporation Business Overview Table 109. Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Product Portfolio Table 111. Mitsubishi Tanabe Pharma Corporation Recent Development Table 112. IQVIA Company Information Table 113. IQVIA Business Overview Table 114. IQVIA Rheumatic Disease Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. IQVIA Rheumatic Disease Drugs Product Portfolio Table 116. IQVIA Recent Development Table 117. Boehringer-Ingelheim Company Information Table 118. Boehringer-Ingelheim Business Overview Table 119. Boehringer-Ingelheim Rheumatic Disease Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Boehringer-Ingelheim Rheumatic Disease Drugs Product Portfolio Table 121. Boehringer-Ingelheim Recent Development Table 122. Aprazer Company Information Table 123. Aprazer Business Overview Table 124. Aprazer Rheumatic Disease Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Aprazer Rheumatic Disease Drugs Product Portfolio Table 126. Aprazer Recent Development Table 127. North America Rheumatic Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Rheumatic Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Rheumatic Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 130. North America Rheumatic Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 131. North America Rheumatic Disease Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Rheumatic Disease Drugs Revenue by Country (2021-2026) & (US$ Million) Table 133. North America Rheumatic Disease Drugs Revenue by Country (US$ Million) & (2027-2032) Table 134. Europe Rheumatic Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 135. Europe Rheumatic Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 136. Europe Rheumatic Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Rheumatic Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Rheumatic Disease Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe Rheumatic Disease Drugs Revenue by Country (2021-2026) & (US$ Million) Table 140. Europe Rheumatic Disease Drugs Revenue by Country (US$ Million) & (2027-2032) Table 141. China Rheumatic Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 142. China Rheumatic Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 143. China Rheumatic Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 144. China Rheumatic Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia Rheumatic Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 146. Asia Rheumatic Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 147. Asia Rheumatic Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 148. Asia Rheumatic Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Rheumatic Disease Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Asia Rheumatic Disease Drugs Revenue by Region (US$ Million) & (2021-2026) Table 151. Asia Rheumatic Disease Drugs Revenue by Region (US$ Million) & (2027-2032) Table 152. SAMEA Rheumatic Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 153. SAMEA Rheumatic Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 154. SAMEA Rheumatic Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 155. SAMEA Rheumatic Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 156. SAMEA Rheumatic Disease Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. SAMEA Rheumatic Disease Drugs Revenue by Country (2021-2026) & (US$ Million) Table 158. SAMEA Rheumatic Disease Drugs Revenue by Country (US$ Million) & (2027-2032) Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Rheumatic Disease Drugs Image Figure 2. Global Rheumatic Disease Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rheumatic Disease Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. DMARDs Image Figure 5. JAK Inhibitors Image Figure 6. Biologics Image Figure 7. Others Image Figure 8. Global Rheumatic Disease Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Rheumatic Disease Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Rheumatic Disease Drugs Market Size (US$ Million) & (2021-2032) Figure 14. Global Rheumatic Disease Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Rheumatic Disease Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Rheumatic Disease Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Rheumatic Disease Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Rheumatic Disease Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Rheumatic Disease Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global Rheumatic Disease Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Rheumatic Disease Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Rheumatic Disease Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Rheumatic Disease Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Rheumatic Disease Drugs Revenue Share by Type (2021-2032) Figure 26. North America Rheumatic Disease Drugs Revenue Share by Application (2021-2032) Figure 27. North America Rheumatic Disease Drugs Revenue Share by Country (2021-2032) Figure 28. United States Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Rheumatic Disease Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Rheumatic Disease Drugs Revenue Share by Type (2021-2032) Figure 33. Europe Rheumatic Disease Drugs Revenue Share by Application (2021-2032) Figure 34. Europe Rheumatic Disease Drugs Revenue Share by Country (2021-2032) Figure 35. Germany Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Rheumatic Disease Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Rheumatic Disease Drugs Revenue Share by Type (2021-2032) Figure 45. China Rheumatic Disease Drugs Revenue Share by Application (2021-2032) Figure 46. Asia Rheumatic Disease Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Rheumatic Disease Drugs Revenue Share by Type (2021-2032) Figure 48. Asia Rheumatic Disease Drugs Revenue Share by Application (2021-2032) Figure 49. Asia Rheumatic Disease Drugs Revenue Share by Region (2021-2032) Figure 50. Japan Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Rheumatic Disease Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Rheumatic Disease Drugs Revenue Share by Type (2021-2032) Figure 58. SAMEA Rheumatic Disease Drugs Revenue Share by Application (2021-2032) Figure 59. SAMEA Rheumatic Disease Drugs Revenue Share by Country (2021-2032) Figure 60. Brazil Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Rheumatic Disease Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • DMARDs
  • JAK Inhibitors
  • Biologics
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Simcere
  • WuXi AppTec
  • Sanofi
  • Johnson & Johnson
  • Roche
  • Eli Lilly and Company
  • ALPHAMAB ONCOLOGY
  • Hengrui
  • Pfizer
  • Henlius
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • UCB
  • Mitsubishi Tanabe Pharma Corporation
  • IQVIA
  • Boehringer-Ingelheim
  • Aprazer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Rheumatic Disease Drugs Market by Type
  3. 1.2.1 Global Rheumatic Disease Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 DMARDs
  5. 1.2.3 JAK Inhibitors
  6. 1.2.4 Biologics
  7. 1.2.5 Others
  8. 1.3 Rheumatic Disease Drugs Market by Application
  9. 1.3.1 Global Rheumatic Disease Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Rheumatic Disease Drugs Market Dynamics
  1. 2.1 Rheumatic Disease Drugs Industry Trends
  2. 2.2 Rheumatic Disease Drugs Industry Drivers
  3. 2.3 Rheumatic Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Rheumatic Disease Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Rheumatic Disease Drugs Market Perspective (2021-2032)
  2. 3.2 Global Rheumatic Disease Drugs Growth Trends by Region
  3. 3.2.1 Global Rheumatic Disease Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Rheumatic Disease Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Rheumatic Disease Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Rheumatic Disease Drugs Revenue by Players
  2. 4.1.1 Global Rheumatic Disease Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Rheumatic Disease Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Rheumatic Disease Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Rheumatic Disease Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Rheumatic Disease Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Rheumatic Disease Drugs Players, Product Type & Application
  8. 4.5 Global Rheumatic Disease Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Rheumatic Disease Drugs Market CR5 and HHI
  11. 4.6.3 2025 Rheumatic Disease Drugs Tier 1, Tier 2, and Tier 3
5 Rheumatic Disease Drugs Market Size by Type
  1. 5.1 Global Rheumatic Disease Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Rheumatic Disease Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Rheumatic Disease Drugs Revenue Market Share by Type (2021-2032)
6 Rheumatic Disease Drugs Market Size by Application
  1. 6.1 Global Rheumatic Disease Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Rheumatic Disease Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Rheumatic Disease Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Simcere
  2. 7.1.1 Simcere Company Information
  3. 7.1.2 Simcere Business Overview
  4. 7.1.3 Simcere Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Simcere Rheumatic Disease Drugs Product Portfolio
  6. 7.1.5 Simcere Recent Developments
  7. 7.2 WuXi AppTec
  8. 7.2.1 WuXi AppTec Company Information
  9. 7.2.2 WuXi AppTec Business Overview
  10. 7.2.3 WuXi AppTec Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 WuXi AppTec Rheumatic Disease Drugs Product Portfolio
  12. 7.2.5 WuXi AppTec Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Rheumatic Disease Drugs Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Johnson & Johnson
  20. 7.4.1 Johnson & Johnson Company Information
  21. 7.4.2 Johnson & Johnson Business Overview
  22. 7.4.3 Johnson & Johnson Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Johnson & Johnson Rheumatic Disease Drugs Product Portfolio
  24. 7.4.5 Johnson & Johnson Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Rheumatic Disease Drugs Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Eli Lilly and Company
  32. 7.6.1 Eli Lilly and Company Company Information
  33. 7.6.2 Eli Lilly and Company Business Overview
  34. 7.6.3 Eli Lilly and Company Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly and Company Rheumatic Disease Drugs Product Portfolio
  36. 7.6.5 Eli Lilly and Company Recent Developments
  37. 7.7 ALPHAMAB ONCOLOGY
  38. 7.7.1 ALPHAMAB ONCOLOGY Company Information
  39. 7.7.2 ALPHAMAB ONCOLOGY Business Overview
  40. 7.7.3 ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Product Portfolio
  42. 7.7.5 ALPHAMAB ONCOLOGY Recent Developments
  43. 7.8 Hengrui
  44. 7.8.1 Hengrui Company Information
  45. 7.8.2 Hengrui Business Overview
  46. 7.8.3 Hengrui Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Hengrui Rheumatic Disease Drugs Product Portfolio
  48. 7.8.5 Hengrui Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Rheumatic Disease Drugs Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 Henlius
  56. 7.10.1 Henlius Company Information
  57. 7.10.2 Henlius Business Overview
  58. 7.10.3 Henlius Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Henlius Rheumatic Disease Drugs Product Portfolio
  60. 7.10.5 Henlius Recent Developments
  61. 7.11 Bristol-Myers Squibb
  62. 7.11.1 Bristol-Myers Squibb Company Information
  63. 7.11.2 Bristol-Myers Squibb Business Overview
  64. 7.11.3 Bristol-Myers Squibb Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bristol-Myers Squibb Rheumatic Disease Drugs Product Portfolio
  66. 7.11.5 Bristol-Myers Squibb Recent Developments
  67. 7.12 Amgen
  68. 7.12.1 Amgen Company Information
  69. 7.12.2 Amgen Business Overview
  70. 7.12.3 Amgen Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Amgen Rheumatic Disease Drugs Product Portfolio
  72. 7.12.5 Amgen Recent Developments
  73. 7.13 AbbVie
  74. 7.13.1 AbbVie Company Information
  75. 7.13.2 AbbVie Business Overview
  76. 7.13.3 AbbVie Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 AbbVie Rheumatic Disease Drugs Product Portfolio
  78. 7.13.5 AbbVie Recent Developments
  79. 7.14 UCB
  80. 7.14.1 UCB Company Information
  81. 7.14.2 UCB Business Overview
  82. 7.14.3 UCB Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 UCB Rheumatic Disease Drugs Product Portfolio
  84. 7.14.5 UCB Recent Developments
  85. 7.15 Mitsubishi Tanabe Pharma Corporation
  86. 7.15.1 Mitsubishi Tanabe Pharma Corporation Company Information
  87. 7.15.2 Mitsubishi Tanabe Pharma Corporation Business Overview
  88. 7.15.3 Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Product Portfolio
  90. 7.15.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
  91. 7.16 IQVIA
  92. 7.16.1 IQVIA Company Information
  93. 7.16.2 IQVIA Business Overview
  94. 7.16.3 IQVIA Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 IQVIA Rheumatic Disease Drugs Product Portfolio
  96. 7.16.5 IQVIA Recent Developments
  97. 7.17 Boehringer-Ingelheim
  98. 7.17.1 Boehringer-Ingelheim Company Information
  99. 7.17.2 Boehringer-Ingelheim Business Overview
  100. 7.17.3 Boehringer-Ingelheim Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Boehringer-Ingelheim Rheumatic Disease Drugs Product Portfolio
  102. 7.17.5 Boehringer-Ingelheim Recent Developments
  103. 7.18 Aprazer
  104. 7.18.1 Aprazer Company Information
  105. 7.18.2 Aprazer Business Overview
  106. 7.18.3 Aprazer Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Aprazer Rheumatic Disease Drugs Product Portfolio
  108. 7.18.5 Aprazer Recent Developments
8 North America
  1. 8.1 North America Rheumatic Disease Drugs Revenue (2021-2032)
  2. 8.2 North America Rheumatic Disease Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Rheumatic Disease Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Rheumatic Disease Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Rheumatic Disease Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Rheumatic Disease Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Rheumatic Disease Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Rheumatic Disease Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Rheumatic Disease Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Rheumatic Disease Drugs Revenue by Country
  11. 8.6.1 North America Rheumatic Disease Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Rheumatic Disease Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Rheumatic Disease Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Rheumatic Disease Drugs Revenue (2021-2032)
  2. 9.2 Europe Rheumatic Disease Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Rheumatic Disease Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Rheumatic Disease Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Rheumatic Disease Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Rheumatic Disease Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Rheumatic Disease Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Rheumatic Disease Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Rheumatic Disease Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Rheumatic Disease Drugs Revenue by Country
  11. 9.6.1 Europe Rheumatic Disease Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Rheumatic Disease Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Rheumatic Disease Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Rheumatic Disease Drugs Revenue (2021-2032)
  2. 10.2 China Rheumatic Disease Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Rheumatic Disease Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Rheumatic Disease Drugs Revenue by Type (2027-2032)
  5. 10.3 China Rheumatic Disease Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Rheumatic Disease Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Rheumatic Disease Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Rheumatic Disease Drugs Revenue by Application (2027-2032)
  9. 10.5 China Rheumatic Disease Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Rheumatic Disease Drugs Revenue (2021-2032)
  2. 11.2 Asia Rheumatic Disease Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Rheumatic Disease Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Rheumatic Disease Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Rheumatic Disease Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Rheumatic Disease Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Rheumatic Disease Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Rheumatic Disease Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Rheumatic Disease Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Rheumatic Disease Drugs Revenue by Country
  11. 11.6.1 Asia Rheumatic Disease Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Rheumatic Disease Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Rheumatic Disease Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Rheumatic Disease Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Rheumatic Disease Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Rheumatic Disease Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Rheumatic Disease Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Rheumatic Disease Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Rheumatic Disease Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Rheumatic Disease Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Rheumatic Disease Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Rheumatic Disease Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Rheumatic Disease Drugs Revenue by Country
  11. 12.6.1 SAMEA Rheumatic Disease Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Rheumatic Disease Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Rheumatic Disease Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst